Ghent University Academic Bibliography

Advanced

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

F Baert, L Moortgat, G Van Assche, P Caenepeel, P Vergauwe, MARTINE DE VOS UGent, P Stokkers, D Hommes, P Rutgeerts and S Vermeire, et al. (2010) GASTROENTEROLOGY. 138(2). p.463-468
abstract
BACKGROUND & AIMS: Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease. METHODS: One-hundred thirty-three newly diagnosed and treatment-naive Crohn's disease patients were given either a combination of immunosuppressive therapy (azathioprine) and 3 infusions of infliximab or treatment with conventional corticosteroids. Patients given azathioprine were given repeated doses of infliximab for relapses, patients given corticosteroids were given azathioprine in cases of corticosteroid dependency and infliximab only if azathioprine failed. A representative subset of 49 patients from the initially randomized cohort underwent ileocolonoscopy after 2 years of therapy. Correlation analysis was performed between different clinical parameters including endoscopic activity (Simple Endoscopic Score) and clinical outcome 2 years after this endoscopic examination. Data were available from 46 patients 3 and 4 years after therapy began. RESULTS: Complete mucosal healing, defined as a simple endoscopic score of 0 after 2 years of therapy, was the only factor that predicted sustained, steroid-free remission 3 and 4 years after therapy was initiated; it was observed in 17 of 24 patients (70.8%) vs 6 of 22 patients with lesions detected by endoscopy (27.3%, Simple Endoscopic Score > 0) (P = .036; odds ratio = 4.352; 95% confidence interval, 1.10-17.220). Fifteen of 17 patients with mucosal healing at year 2 maintained in remission without further infliximab infusions during years 3 and 4 (P = .032; odds ratio = 4.883; 95% confidence interval, 1.144-20.844). CONCLUSIONS: Complete mucosal healing in patients with early-stage Crohn's disease is associated with significantly higher steroid-free remission rates 4 years after therapy began.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
STRATEGIES, RANDOMIZED-TRIAL, INFLIXIMAB
journal title
GASTROENTEROLOGY
Gastroenterology
volume
138
issue
2
pages
463 - 468
Web of Science type
article
Web of Science id
000274300900013
JCR category
GASTROENTEROLOGY & HEPATOLOGY
JCR impact factor
12.032 (2010)
JCR rank
1/71 (2010)
JCR quartile
1 (2010)
ISSN
0016-5085
DOI
10.1053/j.gastro.2009.09.056
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1003962
handle
http://hdl.handle.net/1854/LU-1003962
date created
2010-07-06 12:21:26
date last changed
2010-07-09 10:34:01
@article{1003962,
  abstract     = {BACKGROUND \& AIMS: Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease. METHODS: One-hundred thirty-three newly diagnosed and treatment-naive Crohn's disease patients were given either a combination of immunosuppressive therapy (azathioprine) and 3 infusions of infliximab or treatment with conventional corticosteroids. Patients given azathioprine were given repeated doses of infliximab for relapses, patients given corticosteroids were given azathioprine in cases of corticosteroid dependency and infliximab only if azathioprine failed. A representative subset of 49 patients from the initially randomized cohort underwent ileocolonoscopy after 2 years of therapy. Correlation analysis was performed between different clinical parameters including endoscopic activity (Simple Endoscopic Score) and clinical outcome 2 years after this endoscopic examination. Data were available from 46 patients 3 and 4 years after therapy began. RESULTS: Complete mucosal healing, defined as a simple endoscopic score of 0 after 2 years of therapy, was the only factor that predicted sustained, steroid-free remission 3 and 4 years after therapy was initiated; it was observed in 17 of 24 patients (70.8\%) vs 6 of 22 patients with lesions detected by endoscopy (27.3\%, Simple Endoscopic Score {\textrangle} 0) (P = .036; odds ratio = 4.352; 95\% confidence interval, 1.10-17.220). Fifteen of 17 patients with mucosal healing at year 2 maintained in remission without further infliximab infusions during years 3 and 4 (P = .032; odds ratio = 4.883; 95\% confidence interval, 1.144-20.844). CONCLUSIONS: Complete mucosal healing in patients with early-stage Crohn's disease is associated with significantly higher steroid-free remission rates 4 years after therapy began.},
  author       = {Baert, F and Moortgat, L and Van Assche, G and Caenepeel, P and Vergauwe, P and DE VOS, MARTINE and Stokkers, P and Hommes, D and Rutgeerts, P and Vermeire, S and D'Haens, G and Inflammatory Bowel Dis Res, Belgian and Holland Gut Club, N},
  issn         = {0016-5085},
  journal      = {GASTROENTEROLOGY},
  keyword      = {STRATEGIES,RANDOMIZED-TRIAL,INFLIXIMAB},
  language     = {eng},
  number       = {2},
  pages        = {463--468},
  title        = {Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease},
  url          = {http://dx.doi.org/10.1053/j.gastro.2009.09.056},
  volume       = {138},
  year         = {2010},
}

Chicago
Baert, F, L Moortgat, G Van Assche, P Caenepeel, P Vergauwe, MARTINE DE VOS, P Stokkers, et al. 2010. “Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn’s Disease.” Gastroenterology 138 (2): 463–468.
APA
Baert, F, Moortgat, L., Van Assche, G., Caenepeel, P., Vergauwe, P., DE VOS, M., Stokkers, P., et al. (2010). Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn’s Disease. GASTROENTEROLOGY, 138(2), 463–468.
Vancouver
1.
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, DE VOS M, et al. Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn’s Disease. GASTROENTEROLOGY. 2010;138(2):463–8.
MLA
Baert, F, L Moortgat, G Van Assche, et al. “Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn’s Disease.” GASTROENTEROLOGY 138.2 (2010): 463–468. Print.